S. Pirasath, B. Nageswaran, Rankiri Pathirannahalage Vasana Karunasena, Mathyasekeran Gevakaran
{"title":"Acute abamectin toxicity: a case report","authors":"S. Pirasath, B. Nageswaran, Rankiri Pathirannahalage Vasana Karunasena, Mathyasekeran Gevakaran","doi":"10.1080/24734306.2021.1881233","DOIUrl":"https://doi.org/10.1080/24734306.2021.1881233","url":null,"abstract":"Abstract Abamectin is a potentially fatal agricultural pesticide and antihelmenthic agent. Reports of human toxicity are rare. Here we describe a case of acute poisoning with an abamectin in an adult woman who presented with severe nausea, vomiting, altered consciousness, ptosis, mydriasis, and confusion. She recovered completely recovery with supportive care.","PeriodicalId":23139,"journal":{"name":"Toxicology communications","volume":"38 1","pages":"66 - 68"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72589352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sam Wagner, S. Thornton, L. Oller, Michelle L Wilson, M. Hudson
{"title":"Wild mushroom exposures in Kansas, 2013–2018","authors":"Sam Wagner, S. Thornton, L. Oller, Michelle L Wilson, M. Hudson","doi":"10.1080/24734306.2021.1893972","DOIUrl":"https://doi.org/10.1080/24734306.2021.1893972","url":null,"abstract":"Abstract Background Mushrooms exposures are uncommon, difficult to characterize, and occasionally cause serious morbidity and mortality. We describe mushroom exposures reported to the Kansas Poison Control Center (KSPCC). Methods We queried the KSPCC database for all mushroom exposures from 1 January 2013 to 31 December 2018. We abstracted age, sex, exposure date, reason, management site, laboratory values, medical outcome, GI symptoms, interventions, mycologist consultation, presence of mushroom picture, and identification of the mushroom. Results We identified 441 cases. Typical cases were young children with exploratory ingestion in summer managed at home (279) with no clinical effect (257). Vomiting or diarrhea occurred in 135 cases. Treatments included either no intervention or PO liquids (304), IV fluids (76), anti-emetics (59), or N-acetylcysteine (5). AST was normal in 52 of 55 cases. CPK was high in 3 of 7 patients. Care included hospital admission (56) including ICU in nine. There were no deaths. Most frequently identified were Chlorophyllum (29) and Psilocybe sp. (13). Conclusions Mushroom exposures reported to KPCC were most common in summer months and typically involved unintentional exposures in young children. Vomiting and diarrhea occurred in approximately one-third of cases. Morbidity was minimal. No deaths occurred. In most cases, the mushroom was never identified.","PeriodicalId":23139,"journal":{"name":"Toxicology communications","volume":"70 1","pages":"76 - 81"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79974696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Life threatening hypokalaemia during treatment of severe diltiazem overdose with high dose insulin euglycemic therapy: a case report","authors":"Andrew Kozman, Kerry Hoggett, J. Soderstrom","doi":"10.1080/24734306.2021.1962124","DOIUrl":"https://doi.org/10.1080/24734306.2021.1962124","url":null,"abstract":"Abstract Calcium channel blockers (CCB) overdose can result in cardiogenic shock and that high dose insulin euglycaemic therapy (HIET) is increasingly used to treat CCB poisoning. This case illustrates the risk of severe hypokalaemia resulting from HIET for calcium channel blocker poisoning.","PeriodicalId":23139,"journal":{"name":"Toxicology communications","volume":"108 1","pages":"140 - 142"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81571831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Toxicology communicationsPub Date : 2021-01-01Epub Date: 2021-06-04DOI: 10.1080/24734306.2021.1925444
Richard B van Breemen, John W Hafner, Daniel G Nosal, Douglas L Feinstein, Israel Rubinstein
{"title":"Unmet clinical laboratory need in patients hospitalized for acute poisoning from long-acting anticoagulant rodenticides.","authors":"Richard B van Breemen, John W Hafner, Daniel G Nosal, Douglas L Feinstein, Israel Rubinstein","doi":"10.1080/24734306.2021.1925444","DOIUrl":"10.1080/24734306.2021.1925444","url":null,"abstract":"<p><p>The importance of real-time, quantitative toxicology data available for physicians treating poisoned patients was illustrated during the 2018 outbreak in Illinois of severe coagulopathy caused by inhaling illicit synthetic cannabinoids products contaminated with commercially-available brodifacoum, difenacoum, and bromadiolone, three potent, long-acting anticoagulant rodenticides (LAARs). Identification and quantification of these life-threatening toxins in blood samples of hospitalized patients required toxicology testing with liquid chromatography-tandem mass spectrometry (LC-MS/MS) that was not available in clinical laboratories of hospitals at the time of the outbreak. This highly-sensitive, quantitative assay can provide critical information to guide patient care during and after hospitalization, including identification of offending LAARs, estimates of the ingested dose, and dosage and discontinuation of oral vitamin K<sub>1</sub> therapy after hospital discharge once plasma LAARs concentrations decreased to a safe level (<10 ng/mL). Accordingly, we propose an action plan to enable treating physicians to quantify plasma concentrations of several LAARs simultaneously in poisoned patients. It involves rapid (<15 min), sensitive, and validated LC-MS/MS methods developed, tested and validated in our laboratory. This will allow treating physicians to request quantitative plasma LAARs testing, report test results in the patient's hospital discharge summary, and recommend regular monitoring of plasma LAARs concentrations in the outpatient setting.</p>","PeriodicalId":23139,"journal":{"name":"Toxicology communications","volume":"5 1","pages":"93-96"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39365597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Toxicology communicationsPub Date : 2021-01-01Epub Date: 2021-03-01DOI: 10.1080/24734306.2021.1887637
Daniel G Nosal, Richard B van Breemen, John W Haffner, Israel Rubinstein, Douglas L Feinstein
{"title":"Brodifacoum pharmacokinetics in acute human poisoning: implications for estimating duration of vitamin K therapy.","authors":"Daniel G Nosal, Richard B van Breemen, John W Haffner, Israel Rubinstein, Douglas L Feinstein","doi":"10.1080/24734306.2021.1887637","DOIUrl":"10.1080/24734306.2021.1887637","url":null,"abstract":"<p><p>Standard of care follow-up therapy for patients poisoned by long-acting anticoagulant rodenticides (LAARs) is daily high-dose (up to 100 mg per day) oral vitamin K1 (VK<sub>1</sub>) for weeks to months to over a year. The availability of CLIA-certified quantitative testing for plasma LAAR concentrations can now assist health care providers in determining when to safely discontinue VK<sub>1</sub> therapy. We present estimates of treatment duration required to reach safe concentrations (< =10ng/ml) using serial measurements of plasma brodifacoum (BDF, a potent LAAR) concentrations obtained from patients poisoned after inhaling synthetic cannabinoids containing BDF. We fit the data to zero-order (linear) and first-order (exponential) curves, the latter to account for enterohepatic circulation of BDF. The results show that estimates of therapy duration are significantly longer when exponential clearance is assumed. Accordingly, we recommend that plasma BDF concentrations be monitored simultaneously with international normalization ratio (INR) during follow-up of poisoned patients, and that concentrations be determined after VK<sub>1</sub> therapy is discontinued to document persistence of safe concentrations.</p>","PeriodicalId":23139,"journal":{"name":"Toxicology communications","volume":"5 1","pages":"69-72"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7990043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25531393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Mullins, Mary Yu, L. O'Grady, S. Khan, E. Schwarz
{"title":"Adverse reactions in patients treated with the one-bag method of N-acetylcysteine for acetaminophen ingestion","authors":"M. Mullins, Mary Yu, L. O'Grady, S. Khan, E. Schwarz","doi":"10.1080/24734306.2020.1770498","DOIUrl":"https://doi.org/10.1080/24734306.2020.1770498","url":null,"abstract":"Abstract Acetaminophen (paracetamol) remains the leading pharmaceutical agent in overdoses in North America. The three-bag Prescott protocol for intravenous (IV) acetylcysteine is complex and prone to errors. It has frequent adverse reactions, particularly non-allergic anaphylactoid reactions (NAARs). Over 15 years ago, we adopted a simplified, one-bag protocol using a standard concentration to reduce errors. We report the adverse reactions with this protocol. We used hospital pharmacy records to retrospectively identify patients who received IV acetylcysteine between 12 January 2005 and 20 June 2016. We excluded patients without acetaminophen overdose or with any part of their IV acetylcysteine at an outside hospital. We searched pharmacy records for diphenhydramine or any antiemetic after commencing IV acetylcysteine. We reviewed progress notes for descriptions of nausea, dyspnea, itching/pruritus, or rash. Out of 252 patients receiving IV acetylcysteine, 202 met our inclusion criteria. Thirty-three patients had at least one adverse reaction including nausea in 28 patients and any symptom of NAAR in 8 patients. Twenty-eight patients received an antiemetic. Eleven patients received diphenhydramine (nine for NAAR and two with prochlorperazine). Nausea was the most common adverse reaction. The rate of non-allergic anaphylactoid reactions with the one-bag protocol was 4%.","PeriodicalId":23139,"journal":{"name":"Toxicology communications","volume":"8 1","pages":"49 - 54"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82935455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Fatal occupational selenomethionine poisoning with hazmat response: a case report","authors":"H. Spiller, Judd Shelton, A. Funk","doi":"10.1080/24734306.2020.1731066","DOIUrl":"https://doi.org/10.1080/24734306.2020.1731066","url":null,"abstract":"Abstract A 30-year-old male had an occupational exposure while measuring selenomethionine. He left work due to onset of nausea, weakness and vomiting. He showered and changed clothes at home. Due to continued worsening of symptoms, four hours post-exposure he was brought to an urgent care center (UCC), where he was immediately transported via ambulance to an emergency department (ED). He was noted by UCC and ED staff to have a strong noxious chemical odor. The patient deteriorated rapidly requiring intubation, and PEEP with 100% O2. Naloxone, dextrose, bicarbonate, fluid resuscitation and dopamine infusion were administered. Twenty minutes after arrival, the patient experienced asystole. Resuscitation was not successful. Postmortem blood selenium concentration was 11,000 µg/L. A multi-agency hazmat investigation occurred. The UCC and the patient’s home were locked down. Twenty-four personnel were quarantined on-site for 7 h. Eight employees of the UCC underwent decontamination and transport to an ED for evaluation. Family members and immediate responding officers were quarantined on-site. Volatile methylated forms of selenium excreted in breath and sweat and not residual selenomethionine powder likely caused the chemical odor reported by the ED staff. Secondary contamination of ED personnel is a risk from self-presentation by symptomatic patients after a chemical exposure. Secondary contamination of ED personnel is unlikely from a powdered substance after presentation of a patient who has showered and changed clothes but given the unknown nature at the time, Hazmat Incident Commanders may decide to exercise an abundance of precaution.","PeriodicalId":23139,"journal":{"name":"Toxicology communications","volume":"61 1","pages":"12 - 14"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84246710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"New psychoactive substances (NPS) escape routine drug testing: a case report of phenibut","authors":"T. Breindahl, P. Hindersson, A. Kimergård","doi":"10.1080/24734306.2020.1796342","DOIUrl":"https://doi.org/10.1080/24734306.2020.1796342","url":null,"abstract":"Abstract Phenibut (β − phenyl − γ−aminobutyric acid) is licensed for use as a medicine in countries outside of the European Union (EU), but has also been sold as a “food supplement” from online shops to the general public in the EU. We present a case of phenibut use in a 25-year-old female undergoing alcohol and drug addiction treatment. She reported using phenibut, which she had purchased readily over the internet as a “food supplement.” Our clinical laboratory located in a hospital in the same region received urine samples for analysis which confirmed ingestion of phenibut. Identifying and responding to new psychoactive substances (NPS) emerging on the drug markets poses a challenge to clinical and forensic drug testing. A comprehensive laboratory analysis approach can identify the use of multiple NPS, including those used as medicines, offering beneficial opportunities for drug treatment services and clinical laboratories to work together.","PeriodicalId":23139,"journal":{"name":"Toxicology communications","volume":"43 1","pages":"55 - 58"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74133230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A case of teriflunomide-induced hepatic injury: assessing causality using available rules","authors":"Kathy T. LeSaint, J. Waksman, C. Smollin","doi":"10.1080/24734306.2020.1835413","DOIUrl":"https://doi.org/10.1080/24734306.2020.1835413","url":null,"abstract":"Abstract Teriflunomide, a pyrimidine synthesis inhibitor approved for treatment for the relapsing form of multiple sclerosis, has been deemed reasonably safe though hepatic toxicity is a rare serious adverse event. We report an uncommon case of a 48-year-old man who developed severe hepatotoxicity within a short time after initiation of teriflunomide treatment with resolution of signs and symptoms after drug discontinuation and concomitant treatment with cholestyramine. In this case, we provide a general framework regarding the assignment of causation in potential causes of drug-induced liver injury. The patient met the case definition of Hy’s law and his hepatotoxicity was assessed as causally related to teriflunomide using the Roussel Uclaf Causality Assessment Method (RUCAM).","PeriodicalId":23139,"journal":{"name":"Toxicology communications","volume":"131 1","pages":"62 - 66"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73409655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Neurological effects of chronic occupational exposure to alcohol mists and vapors in a machinist","authors":"Marcia H Ratner, W. M. Ewing, J. Rutchik","doi":"10.1080/24734306.2020.1768341","DOIUrl":"https://doi.org/10.1080/24734306.2020.1768341","url":null,"abstract":"Abstract Here we report a rare case of reversible neurological symptoms due to chronic ethanol vapor and mist exposure in a 50-year-old machinist who intentionally used undiluted 200 proof ethanol as a cutting fluid while turning metal machine parts on a toolroom lathe for a period of 3 years. Shortly after switching to ethanol as a cutting fluid, the worker began to experience central nervous system symptoms including headaches, fatigue, ataxia, and concentration and memory problems. Clinical neuropsychological assessment revealed mild deficits on tests of attention, executive function, and memory. The worker was subsequently advised to stop using ethanol as a cutting fluid. At follow-up after cessation of exposure the worker reported that his symptoms were remarkably improved.","PeriodicalId":23139,"journal":{"name":"Toxicology communications","volume":"54 1","pages":"43 - 48"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74997120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}